hVIVO plc


 AIM: HVO


£22m raised since 2019


Development. Innovation. Returns.

hVIVO plc (formerly Open Orphan plc) is a fast-growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Group has world class challenge agent manufacturing capabilities, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group also offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO runs challenge trials in London - its new state-of-the-art facilities in Canary Wharf opened in 2024 and is the world's largest commercial human challenge trial unit, with highly specialised on-site virology and immunology laboratories, and an outpatient unit. To recruit volunteers / patients for its studies, the Group leverages its unique clinical trial recruitment capability via its FluCamp volunteer screening facilities in London and Manchester.

hVIVO is now the world’s leading provider of human challenge trials, with revenues increased by over 50% in the last two years. I am proud of the strong, profitable company it is today.
— Cathal Friel

Our Other IPO Companies

Poolbeg Pharma plc

  • Spun out of Open Orphan & listed on AIM in July 2021. Commenced trading on OTCQB in the US in March 2022.

Amryt Pharma plc

  • Listed on AIM and Euronext in 2016, raising £20m in funding. Listed on Nasdaq in 2020 and was sold for $1.48bn in 2023.

Fastnet Oil & Gas plc

  • Raised over $50m through its floatation on the London and Dublin stock exchanges.

European Green Transition

  • A privately-owned green transition focused company developing a portfolio of green economy assets in Europe.